Ageing skin has long been described in the language of what is lost — collagen, elastin, hydration, luminosity. A more precise account is emerging in the clinical literature, and it reframes ageing not as passive depletion but as a chronic, low-grade inflammatory state. This is the microinflammation theory of ageing, often termed inflammaging, and it is reshaping how sophisticated practitioners think about the skin.
From wrinkles to a signalling problem
Inflammaging describes a persistent, sterile, low-level inflammatory tone that accumulates with age. It is driven in large part by senescent cells — cells that have exited the cell cycle yet remain metabolically active, secreting a cocktail of pro-inflammatory cytokines, matrix-remodelling enzymes and growth factors known as the senescence-associated secretory phenotype (SASP). In the dermis, this translates into fibroblast dysfunction, extracellular matrix degradation, impaired barrier repair and the visible signatures of age.
Critically, this is a communication pathology. Senescent fibroblasts and keratinocytes broadcast SASP signals that push neighbouring healthy cells toward a senescent, pro-inflammatory phenotype — a feed-forward loop that quietly accelerates tissue decline and delays repair.
Where extracellular vesicles enter the story
Extracellular vesicles are central to this signalling economy. Fibroblast-derived vesicles can act as amplifiers of chronic inflammation, disseminating pro-inflammatory cargo across the dermal microenvironment. The same biology that drives inflammaging is, in other words, vesicle-mediated.
This is precisely why exosome technology has attracted clinical interest. Exosomes are nanoscale vesicles, roughly 30–150 nm, that carry proteins, lipids, messenger RNA and microRNA between cells. Regenerative exosome preparations are studied for their capacity to modulate the inflammatory tone of tissue — supporting fibroblast function and a pro-repair signalling environment rather than simply adding a raw material to the skin.
A mechanism-led clinical narrative
For the practitioner, the value of the inflammaging model is strategic. It repositions regenerative work from cosmetic correction toward biological modulation: the aim is not only to fill or resurface, but to influence the signalling environment that governs how skin ages. Exosome-based actives sit naturally within that narrative — as a way to speak to the cell, not merely to the surface.
The evidence base is still maturing, and much of the mechanistic data remains preclinical. But the direction of travel is clear. Practitioners who understand ageing as a signalling disorder are better placed to build treatment plans — and patient conversations — around cause rather than symptom.